SARC Biannual Meeting
November 13, 2008
The Landmark Hotel, London, UK
8:00 am - 12:00 pm

AGENDA

Thursday, November 13, 2008
8:00 – 8:15	Welcome/SARC Update	Laurence Baker Chair, SARC Board of Directors
8:15 – 8:45	Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 1)
	Laboratory Investigation of Resistant GIST	Jonathan Fletcher
8:45– 10:15	Review of Ongoing SARC Trials
	SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma	Elizabeth Fox
	SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP	Scott Schuetze
	SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma	Martee L. Hensley
	SARC 006 Phase 2 MPNST: Sporadic versus NF1 associated	Lee Helman
	SARC 007 Phase 2 Perifosine in chemoinsensitive sarcoma	Jonathan Trent
	SARC 009 Phase 2 Dasatinib in metastatic sarcoma	Scott Schuetze
	SARC 011 Phase 2 IGF-1R in selected sarcomas	Alberto Pappo
	SARC011 Companion Biology Protocol	Lee Helman
	SARC 012 Phase 2 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung	Lee Helman Su Kim*
10:15—10:45	Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 2)
	New Approaches to GIST	Meg von Mehren
10:45– 11:15	Review of Pending Trials
	SARC 013 Phase 3 IGF-1R/Ewings	Herbert Jürgens* Paul Meyers Shreyas Patel
	SARC014 Phase 1 IGF-1R/Rapamycin	Richard Gorlick
	SARC015 Phase 2 IGF-1R in WT GIST	Meg von Mehren Katie Janeway*
	SARC016 Phase 2 Everolimus/MPNST	Lee Helman
	SARC018 Phase 2 Desmoid Surgery/Radiation	Robert Benjamin

11:15 – 11:30	SARC Restructuring
	Participating Committee	Suzanne George
	Medical Officer and New Concepts	Denise Reinke
11:30-12:00	Closed Session: SARC Business Update (SARC Participants Only)

	* Presenter